No quarterly revenue total was found in Genprex, Inc.'s SEC filings.
Genprex, Inc. (GNPX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-4.45M
+4.9% vs year-ago quarter
Operating cash flow
$-5.14M
-33.0% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
819,709
-97.6% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GNPX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1595248
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.5M | -$4.5M | -$3.5M | -$3.3M | -$4.7M |
| Net income | -$4.4M | -$4.5M | -$3.8M | -$3.8M | -$4.7M |
| Operating cash flow | -$5.1M | -$3.1M | -$4.1M | -$3.2M | -$3.9M |
| Total assets | $17.1M | $20.3M | $10.2M | $3.6M | $3.8M |
| Total liabilities | $2.3M | $3.4M | $2.2M | $2.8M | — |
| Stockholders' equity | $14.8M | $16.9M | $8.0M | $767,807 | $1.4M |
| Cash and investments | $15.2M | $18.0M | $7.8M | $1.1M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 491 Genprex, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.